Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting

Clinical Therapeutics
M J NuijtenErik Hoencamp

Abstract

This study assessed the cost-effectiveness of escitalopram for the treatment of depression in the Netherlands from a societal perspective. A decision tree model was constructed using decision analytical techniques. Data sources included published literature, clinical trials, official price/tariff lists, national population statistics, and Delphi panel data. The comparators were venlafaxine XR and citalopram. The primary perspective of this health economic evaluation was that of the society in the Netherlands in 2010. The time horizon was 26 weeks. The effectiveness outcomes of the study were quality-adjusted life-years (QALYs). Escitalopram was associated with a cost savings per patient of €263 versus venlafaxine XR and €1992 versus citalopram over a period of 26 weeks from a societal perspective. Escitalopram was also associated with a gains QALYs: 0.0062 versus venlafaxine XR and 0.0166 versus citalopram. Escitalopram was dominant over both venlafaxine XR and citalopram. Based on the findings from this cost-effectiveness analysis, the favorable clinical benefit of escitalopram resulted in a positive health economic benefit in the Netherlands.

References

Oct 1, 1992·Archives of General Psychiatry·G L Klerman, M M Weissman
Nov 21, 1990·JAMA : the Journal of the American Medical Association·W E BroadheadC K Tse
Jul 1, 1989·Social Psychiatry and Psychiatric Epidemiology·J OrmelR Sanderman
Nov 1, 1986·General Hospital Psychiatry·A StoudemireD Blazer
Sep 1, 1994·Fortschritte der Neurologie-Psychiatrie·M B Keller
Nov 14, 2001·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·M J Nuijten
May 14, 2004·CNS Drugs·Katherine F Croom, Greg L Plosker
May 26, 2004·Psychopharmacology·Connie SánchezClaus Braestrup
Jun 18, 2004·Current Medical Research and Opinion·Michiel E H HemelsThomas R Einarson
Sep 16, 2004·The Journal of Clinical Psychiatry·Robert J BielskiChung-Chi Chang
Feb 8, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Fenghua ChenOve Wiborg
Aug 1, 2006·International Clinical Psychopharmacology·Stuart A Montgomery, Henning F Andersen
Aug 22, 2006·Basic & Clinical Pharmacology & Toxicology·Connie Sánchez
Feb 13, 2007·International Clinical Psychopharmacology·Bruno FantinoJean-Paul Auray
Nov 11, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Michael DrummondJohan Severens
Nov 3, 2010·Current Medical Research and Opinion·Antoni Sicras-MainarJordi Salvatella-Pasant
Jun 30, 2011·Frontiers in Pharmacology·Mark J C Nuijten, Dominique J Dubois

❮ Previous
Next ❯

Citations

Feb 16, 2013·ClinicoEconomics and Outcomes Research : CEOR·Claudio MencacciClaudio Ripellino
Jun 26, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Qi CaoErik Buskens
Feb 15, 2018·PharmacoEconomics Open·Spyros KolovosMaurits W van Tulder
Sep 24, 2020·Health Economics Review·Juliane Andrea DuevelWolfgang Greiner

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.